AXGN Quote, Financials, Valuation and Earnings

Electromed, Inc. has a net margin of -21.96% compared to Axogen, Inc.'s net margin of 14.61%. Axogen, Inc.'s return on equity of -13.75% beat Electromed, Inc.'s return on equity of 20.35%.

Axogen, Inc. has a consensus price target of $39.20, signalling upside risk potential of 23.54%. On the other hand Electromed, Inc. has an analysts' consensus of $37.00 which suggests that it could grow by 56.12%. Given that Electromed, Inc. has higher upside potential than Axogen, Inc., analysts believe Electromed, Inc. is more attractive than Axogen, Inc..

Axogen, Inc. has a beta of 0.982, which suggesting that the stock is 1.752% less volatile than S&P 500. In comparison Electromed, Inc. has a beta of 0.300, suggesting its less volatile than the S&P 500 by 70.034%.

Axogen, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axogen, Inc. pays -- of its earnings as a dividend. Electromed, Inc. pays out -- of its earnings as a dividend.

Axogen, Inc. quarterly revenues are $59.9M, which are larger than Electromed, Inc. quarterly revenues of $18.9M. Axogen, Inc.'s net income of -$13.2M is lower than Electromed, Inc.'s net income of $2.8M. Notably, Axogen, Inc.'s price-to-earnings ratio is -- while Electromed, Inc.'s PE ratio is 23.07x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axogen, Inc. is 6.66x versus 3.02x for Electromed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Escalon Medical Corp. has a net margin of -21.96% compared to Axogen, Inc.'s net margin of 2.72%. Axogen, Inc.'s return on equity of -13.75% beat Escalon Medical Corp.'s return on equity of -12.94%.

Axogen, Inc. has a consensus price target of $39.20, signalling upside risk potential of 23.54%. On the other hand Escalon Medical Corp. has an analysts' consensus of -- which suggests that it could grow by 4700%. Given that Escalon Medical Corp. has higher upside potential than Axogen, Inc., analysts believe Escalon Medical Corp. is more attractive than Axogen, Inc..

Axogen, Inc. has a beta of 0.982, which suggesting that the stock is 1.752% less volatile than S&P 500. In comparison Escalon Medical Corp. has a beta of 0.232, suggesting its less volatile than the S&P 500 by 76.837%.

Axogen, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Escalon Medical Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axogen, Inc. pays -- of its earnings as a dividend. Escalon Medical Corp. pays out -- of its earnings as a dividend.

Axogen, Inc. quarterly revenues are $59.9M, which are larger than Escalon Medical Corp. quarterly revenues of $3.6M. Axogen, Inc.'s net income of -$13.2M is lower than Escalon Medical Corp.'s net income of $97.7K. Notably, Axogen, Inc.'s price-to-earnings ratio is -- while Escalon Medical Corp.'s PE ratio is 154.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axogen, Inc. is 6.66x versus 0.22x for Escalon Medical Corp.. Usually stocks with elevated PS ratios are considered overvalued.

IRIDEX Corp. has a net margin of -21.96% compared to Axogen, Inc.'s net margin of -12.6%. Axogen, Inc.'s return on equity of -13.75% beat IRIDEX Corp.'s return on equity of -155.93%.

Axogen, Inc. has a consensus price target of $39.20, signalling upside risk potential of 23.54%. On the other hand IRIDEX Corp. has an analysts' consensus of $3.00 which suggests that it could grow by 114.29%. Given that IRIDEX Corp. has higher upside potential than Axogen, Inc., analysts believe IRIDEX Corp. is more attractive than Axogen, Inc..

Axogen, Inc. has a beta of 0.982, which suggesting that the stock is 1.752% less volatile than S&P 500. In comparison IRIDEX Corp. has a beta of 0.674, suggesting its less volatile than the S&P 500 by 32.591%.

Axogen, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IRIDEX Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axogen, Inc. pays -- of its earnings as a dividend. IRIDEX Corp. pays out -- of its earnings as a dividend.

Axogen, Inc. quarterly revenues are $59.9M, which are larger than IRIDEX Corp. quarterly revenues of $12.5M. Axogen, Inc.'s net income of -$13.2M is lower than IRIDEX Corp.'s net income of -$1.6M. Notably, Axogen, Inc.'s price-to-earnings ratio is -- while IRIDEX Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axogen, Inc. is 6.66x versus 0.46x for IRIDEX Corp.. Usually stocks with elevated PS ratios are considered overvalued.